Activation of JNK by hgal9 (a recombinant protease resistant galectin-9), or plinabulin (a novel vascular disrupting agent), or perifosine (an Akt inhibitor) has previously been reported in MM cells [23], [24], [33]. This evidence concerns the gene AKT1 and Miyoshi myopathy.